Want to see GB:EDEN full AI Analyst Report?
Eden Research (EDEN) AI Stock Analysis
Eden Research
(LSE:EDEN)
The score is constrained primarily by ongoing losses and negative cash flow, despite strong revenue growth and a low-debt balance sheet. Positive technical positioning provides some support, but extremely overbought momentum and the negative P/E ratio keep the overall score modest.
Eden Research (EDEN) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 25.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 667.61K
- Price to Earnings (P/E)
- -8.8
- Beta (1Y)
- 1.17
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 23
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Agricultural Inputs
Eden Research Business Overview & Revenue Model
Company Description
Eden BioSolutions Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The firm provides various plant protection products, such as foliar disease control, soil pest, prot...
How the Company Makes Money
Eden Research primarily makes money by commercialising its bio-based crop protection products and technology through licensing and distribution arrangements with partners. Revenue is generated mainly from (1) product sales and related partner purchas...
Eden Research Financial Statement Overview
Summary
Revenue has grown strongly and borrowings are low, but persistent operating losses and consistently negative operating and free cash flow materially weaken the financial profile.
Income Statement
42NeutralBalance Sheet
63PositiveCash Flow
32Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.62M | 3.88M | 4.30M | 3.19M | 1.83M | 1.23M |
| Gross Profit | 1.39M | 1.14M | 1.87M | 1.77M | 207.14K | 28.32K |
| EBITDA | -1.68M | -1.56M | -1.59M | -6.24M | -1.83M | -2.72M |
| Net Income | -2.35M | -1.96M | -1.91M | -6.49M | -2.24M | -2.79M |
Balance Sheet | ||||||
| Total Assets | 13.46M | 16.34M | 15.41M | 16.59M | 12.91M | 15.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 1.52M | 3.67M | 7.41M | 1.99M | 3.83M |
| Total Debt | 571.86K | 671.91K | 168.73K | 229.77K | 355.32K | 398.35K |
| Total Liabilities | 2.85M | 3.91M | 3.57M | 3.05M | 2.17M | 2.20M |
| Stockholders Equity | 10.58M | 12.42M | 11.82M | 13.52M | 10.72M | 12.80M |
Cash Flow | ||||||
| Free Cash Flow | -710.00K | -2.45M | -3.60M | -1.80M | -1.74M | -3.34M |
| Operating Cash Flow | -209.90K | -2.44M | -1.01M | -1.70M | -683.10K | -1.62M |
| Investing Cash Flow | -2.72M | -2.41M | -2.48M | -1.72M | -1.05M | -1.73M |
| Financing Cash Flow | -150.87K | 2.64M | -155.53K | 8.90M | -150.35K | -90.39K |
Eden Research Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Positive. The current price of 3.82 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.32, and above the 200-day MA of 3.03, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 92.29 is Negative, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EDEN.
Eden Research Peers Comparison
Overall Rating
GB:ELM73Outperform
GB:CRDA66Neutral
GB:ITX58Neutral
GB:SYNT53Neutral- GB:EDEN51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:ELM | 73Outperform | GBP 1.06B | 19.36 | 11.29% | 1.78% | -11.73% | ― |
| GB:CRDA | 66Neutral | GBP 5.09B | 64.43 | 3.65% | 3.05% | 3.36% | -43.08% |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| GB:ITX | 58Neutral | GBP 23.94M | -25.57 | -15.42% | ― | 57.55% | 2.94% |
| GB:SYNT | 53Neutral | GBP 181.98M | -1.52 | -13.27% | ― | -4.98% | -43.98% |
| GB:EDEN | 51Neutral | GBP 25.31M | -8.75 | -16.16% | ― | ― | ― |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:EDEN | Eden Research | 3.15 | 0.65 | 26.00% | |
| GB:CRDA | Croda International | 3644.00 | 942.70 | 34.90% | |
| GB:ELM | Elementis plc | 187.20 | 29.95 | 19.05% | |
| GB:ITX | Itaconix plc | 177.50 | 71.50 | 67.45% | |
| GB:SYNT | Synthomer plc | 111.00 | 61.00 | 122.00% |
Eden Research Corporate Events
Eden BioSolutions targets partnerships at global biocontrol summit
PositiveEden BioSolutions will send its chief executive Sean Smith, chief financial officer Alex Abrey and other commercial team members to the Annual Biocontrol Industry Meeting in Basel from 20 to 22 October 2026. The event is a key gathering for the globa...
Eden BioSolutions plans investor update as sustainable biopesticide portfolio grows
PositiveEden BioSolutions plc, a specialist in sustainable biopesticides and biocontrol technologies, serves global agriculture and related sectors with plant‑based crop protection products and plastic‑free microencapsulation solutions. Its comme...
Eden Research Rebrands as Eden BioSolutions to Sharpen Biopesticide Focus
PositiveEden BioSolutions, a UK-listed leader in sustainable biopesticides and biocontrol technologies, serves global crop protection, animal health and consumer markets with plant-derived products aimed at high-value fruits, vegetables and seed treatments....
Eden Research Wins AGM Backing and Rebrands as Eden BioSolutions
PositiveEden Research plc, the AIM-quoted biopesticides specialist, has secured strong shareholder backing at its Annual General Meeting, with all resolutions passed, including the reappointment of board members and authorities related to share issuance and...
Eden Research uses AGM to showcase regulatory wins and expanding biopesticide pipeline
PositiveEden Research’s AGM statement highlights continued momentum in building its position as an emerging leader in biological crop protection, with fresh commercial and regulatory milestones for its existing products. Recent progress includes Califo...
Eden Research Wins EPA Label Expansion for Mevalone in Key U.S. Market
PositiveEden Research, the only UK-listed company focused solely on biopesticides for sustainable agriculture, develops terpene-based crop protection products and plastic-free Sustaine microencapsulation for use on high-value fruits, vegetables and other cro...
Eden Research Grants Long-Term Incentive Options Tied to Shareholder Returns and Revenue Targets
PositiveEden Research has granted 33,737,659 options over new ordinary shares under its Long Term Incentive Plan for calendar year 2025, aligning staff rewards with future performance. The awards include 7,101,189 options for chief executive Sean Smith, 5,33...
Eden Research posts 2026 accounts and sets date for AGM
PositiveEden Research plc, the AIM‑quoted biopesticides and biocontrol specialist, has published its Annual Report and Accounts for the fifteen‑month period to 31 March 2026 and circulated the Notice of its upcoming Annual General Meeting. The AG...
Eden Research boosts revenue and global approvals as losses widen
PositiveEden Research reported preliminary results for the 15 months to 31 March 2026, with revenue rising to £4.9 million but operating losses widening to £2.9 million and cash falling to £1.5 million. The company completed a £10.8 milli...
Eden Research sets date for 2026 preliminary results and investor briefing
PositiveEden Research plc, a UK-listed leader in sustainable biopesticides and biocontrol technologies, develops plant-derived crop protection products and a biodegradable microencapsulation platform for global agriculture and related markets. Its key offeri...
Eden Research Wins Mevalone Approvals in Slovakia and Egypt, Opening North African Market
PositiveEden Research has secured regulatory approvals for its Botrytis fungicide Mevalone in Slovakia and, under the Trilogy brand, in Egypt, extending its reach in both Central Europe and North Africa. In Slovakia, the product will be marketed by Biocont f...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026